Patient demography
dry eye disease
Among the 259 patients who were screened for this study, 222 participants were randomized to one of three treatment groups. Two patients were excluded due to non-administration of investigational drug and a total of 220 eyes of 220 participants (of 222 enrolled participants) – 74 in the 1% rebamipide group, 72 in the 2% rebamipide group, and 74 in the placebo group – were included in the FAS. In total, 189 (85.9%) participants completed the study as per protocol and were included in the PPS (Fig. 
Flow diagram of a randomized controlled trial for assessing the efficacy and safety of 1% and 2% rebamipide clear solution in patients with dry eye disease
Baseline characteristics of the participants (n = 220)* One-way analysis of variance† Chi-square test